• Home
  • About IBT
    • IBT History
    • Management
    • Board of Directors
    • Advisory Board
    • Sustainability Policy
  • Pipeline
    • IBP-9414
    • IBP-1016
    • IBP-1118
    • IBP-1122
    • Expanded Access Policy for Investigational Drugs
  • Families
  • Healthcare Professionals
  • Investors & Media
    • Shares
    • Presentations
    • Share Issue
    • Ownership Structure
    • Corporate Governance
    • Calendar
    • Financial Reports
    • Press Releases
    • Investors & Media Contact
  • Contact Us
  • Career
IBT Logo IBT Logo
  • En
  • Sv
  • Home
  • About IBT
    • IBT History
    • Management
    • Board of Directors
    • Advisory Board
    • Sustainability Policy
  • Pipeline
    • IBP-9414
    • IBP-1016
    • IBP-1118
    • IBP-1122
    • Expanded Access Policy for Investigational Drugs
  • Families
  • Healthcare Professionals
  • Investors & Media
    • Shares
    • Presentations
    • Share Issue
    • Ownership Structure
    • Corporate Governance
    • Calendar
    • Financial Reports
    • Press Releases
    • Investors & Media Contact
  • Contact Us
  • Career


Josef Neu, M.D.
May 23, 2018

Latest press releases

2025-12-11 18:05 Infant Bacterial Therapeutics secures partnership with BioConnection for production of Drug Product
2025-11-25 18:41 IBT changes the IBP-9414 pathway for approval following discussions with the FDA Regulatory MAR
2025-11-20 16:42 Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for production of drug substance
2025-11-13 07:30 Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2025 Regulatory
2025-10-20 10:35 Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2026 Regulatory
Contact | info@ibtherapeutics.com
© Copyright Infant Bacterial Therapeutics AB 2026
Cookie Policy Privacy Policy Terms of Use